FIELD: biotechnology.
SUBSTANCE: invention relates to a method of producing a live vaccine on the basis of biologically active strain Enterococcus faecium L3 due to the itrogression of the antigen of a clinically relevant pathogenic microorganism into the structure of the strain piles. This method involves producing a fusion gene of entF-bac, consisting of two separate gene fragments of probiotic E.faecium L3 and gene fragment bac and having a nucleotide sequence, shown in fig. 7a, its cloning and detection of bacterial clones expressing the desired protein in piles. The invention also relates to recombinant plasmid DNA pentF-bac. The real DNA pentF-bac is designed to create a live vaccine based on the biologically active strain of E. faecium L3. This pentF-bac DNA is a suicide plasmid pT7ERMB, at BamHI and KpnI sites of which the sequence of entF-bac fusion gene DNA is inserted. The present invention also relates to a vaccine preparation of E.faecium L3 Bac+. This vaccine preparation is prepared by electroporation of E. faecium L3 of plasmid pentF-bac DNA.
EFFECT: invention allows for the production of a live vaccine based on the biologically active strain.
3 cl, 9 dwg, 1 tbl, 5 ex
Title | Year | Author | Number |
---|---|---|---|
LIVE VACCINE BASED ON ENTEROCOCCUS FAECIUM L3 PROBIOTIC STRAIN FOR PREVENTION OF INFECTION CAUSED BY STREPTOCOCCUS PNEUMONIE | 2018 |
|
RU2701733C1 |
METHOD OF CREATING A LIVE VACCINE AGAINST COVID-19 BASED ON THE PROBIOTIC STRAIN ENTEROCOCCUS FAECIUM L3 AND A LIVE VACCINE ENTEROCOCCUS FAECIUM L3-PENTF-COVID-19 | 2020 |
|
RU2745626C1 |
METHOD FOR CREATING RECOMBINANT ENTEROCOCCUS L3-SARSN1 STRAIN BASED ON BIOLOGICALLY ACTIVE ENTEROCOCCUS FAECIUM L3 STRAIN | 2022 |
|
RU2820058C1 |
METHOD FOR CREATING LIVE STRAIN OF ENTEROCOCCUS L3-SARS BASED ON BIOLOGICALLY ACTIVE STRAIN OF E. FAECIUM L3 | 2021 |
|
RU2782529C1 |
COMPLEX OF RECOMBINANT POLYPEPTIDES WITH PROTECTIVE PROPERTIES IN RELATION TO STREPTOCOCCUS AGALACTIAE AND STREPTOCOCCUS PYOGENES | 2014 |
|
RU2587627C2 |
RECOMBINANT DNA PROVIDING PRODUCTION OF POLYPEPTIDES P6, P7, P8 EXHIBITING PROTECTIVE PROPERTIES AGAINST STREPTOCOCCUS AGALACTIAE AND SELECTIVELY CONNECTING IgA | 2008 |
|
RU2387715C2 |
RECOMBINANT DNA ENSURING PRODUCTION OF THE RECOMBINANT PROTEIN COV1 EXHIBITING IMMUNOGENIC PROPERTIES AGAINST SARS-COV-2 VIRUS | 2021 |
|
RU2776484C1 |
RECOMBINANT DNA ENSURING PRODUCTION OF RECOMBINANT PROTEIN PBI EXPRESSING PROTECTIVE PROPERTIES IN RELATION TO STREPTOCOCCUS PYOGENES AND STREPTOCOCCUS AGALACTIAE | 2008 |
|
RU2378374C2 |
ENTEROCOCCUS STRAIN ENTEROCOCCUS FAECIUM L-3 FOR THE TREATMENT AND PREVENTION OF BACTERIAL AND VIRAL INFECTIONS USING THERAPEUTIC AND PROPHYLACTIC AGENTS AND FOOD PRODUCTS MADE ON ITS BASIS AND A METHOD OF CULTIVATING THE ENTEROCOCCUS STRAIN ENTEROCOCCUS FAECIUM L-3 | 2022 |
|
RU2800359C1 |
STRAIN OF Lactobacillus fermentum Z, USED FOR PRODUCTION OF PROBIOTIC CULTURED MILK FOODS | 2008 |
|
RU2412239C2 |
Authors
Dates
2017-12-27—Published
2015-10-23—Filed